AKLI logo

Akili (AKLI) Stock

Profile

Full Name:

Akili, Inc.

Sector:

Healthcare

Country:

United States

IPO:

30 June 2021

Indexes:

Not included

Description:

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts. As of July 1, 2024, Akili, Inc. operates as a subsidiary of Virtual Therapeutics Corp.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Aug 09, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

11 Aug '23 Credit Suisse
Outperform
25 Jan '23 Morgan Stanley
Equal-Weight
28 Dec '22 Morgan Stanley
Equal-Weight
18 Nov '22 B of A Securities
Neutral
15 Nov '22 Credit Suisse
Outperform
25 Oct '22 Credit Suisse
Outperform
06 Sept '22 Cowen & Co.
Outperform

Screeners with AKLI included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI
AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI
AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI
AKLI
prnewswire.com14 June 2024

NEW ORLEANS , June 14, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of Shareholders
AKLI
accesswire.com06 June 2024

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Akili, Inc. (NASDAQ:AKLI)'s sale to Virtual Therapeutics for $0.4340 per share of common stock in cash. If you are an Akili shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, SGE on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, SGE on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, SGE on Behalf of Shareholders
AKLI
accesswire.com06 June 2024

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Akili, Inc. (NASDAQ:AKLI)'s sale to Virtual Therapeutics for $0.4340 per share of common stock in cash. If you are an Akili shareholder, click here to learn more about your rights and options.

AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI
AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI
AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI
AKLI
accesswire.com05 June 2024

NEW ORLEANS, LA / ACCESSWIRE / June 5, 2024 / Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, WIRE on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, WIRE on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, WIRE on Behalf of Shareholders
AKLI
globenewswire.com05 June 2024

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. – AKLI
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. – AKLI
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. – AKLI
AKLI
globenewswire.com05 June 2024

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Akili , Inc. ( NASDAQ: AKLI ), relating to a tender offer from Vital Therapeutics Corporation. Under the terms of the agreement, Vital Therapeutics Corporation will acquire all the outstanding shares of Akili common stock for $0.4340 cash per share.

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. - AKLI
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. - AKLI
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. - AKLI
AKLI
prnewswire.com04 June 2024

NEW YORK , June 4, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Akili, Inc. (NASDAQ: AKLI), relating to a tender offer from Vital Therapeutics Corporation.

PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
AKLI
businesswire.com29 May 2024

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Interactive and Virtual Therapeutics Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company.

Shareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public Shareholders
AKLI
prnewswire.com29 May 2024

MILWAUKEE , May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Akili (Nasdaq: AKLI) for possible breaches of fiduciary duty and other violations of law in its transaction with Virtual Therapeutics. Click here to learn how to join the https://www.ademilaw.com/case/akili-inc or call Guri Ademi toll-free at 866-264-3995.

Why Is Akili (AKLI) Stock Up 68% Today?
Why Is Akili (AKLI) Stock Up 68% Today?
Why Is Akili (AKLI) Stock Up 68% Today?
AKLI
InvestorPlace30 April 2024

Akili (NASDAQ: AKLI) stock is surging today following a positive corporate update from the digital medicine company. Shionogi has forgiven and canceled $5 million in debt owed by Akili, contributing to the stock's rise.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Akili?
  • What is the ticker symbol for Akili?
  • Does Akili pay dividends?
  • What sector is Akili in?
  • What industry is Akili in?
  • What country is Akili based in?
  • When did Akili go public?
  • Is Akili in the S&P 500?
  • Is Akili in the NASDAQ 100?
  • Is Akili in the Dow Jones?
  • When was Akili's last earnings report?
  • When does Akili report earnings?
  • Should I buy Akili stock now?

What is the primary business of Akili?

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts. As of July 1, 2024, Akili, Inc. operates as a subsidiary of Virtual Therapeutics Corp.

What is the ticker symbol for Akili?

The ticker symbol for Akili is NASDAQ:AKLI

Does Akili pay dividends?

No, Akili does not pay dividends

What sector is Akili in?

Akili is in the Healthcare sector

What industry is Akili in?

Akili is in the Health Information Services industry

What country is Akili based in?

Akili is headquartered in United States

When did Akili go public?

Akili's initial public offering (IPO) was on 30 June 2021

Is Akili in the S&P 500?

No, Akili is not included in the S&P 500 index

Is Akili in the NASDAQ 100?

No, Akili is not included in the NASDAQ 100 index

Is Akili in the Dow Jones?

No, Akili is not included in the Dow Jones index

When was Akili's last earnings report?

Akili's most recent earnings report was on 9 August 2024

When does Akili report earnings?

The date for Akili's next earnings report has not been announced yet

Should I buy Akili stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions